Hansa Biopharma AB, (Hansa), pioneer in enzyme technology for rare immunological conditions, announces the completion of enrollment in its phase 2 study evaluating safety, tolerability and efficacy of imlifidase in patients with active and chronic active antibody mediated rejection (AMR) episodes. A first data read out is expected in the second half of 2022, as previously guided.
